Research Overview: Ultima-Clen-Salbuto (EU) Ultima Pharmaceuticals
Ultima-Clen-Salbuto is a dual beta-2 adrenergic agonist formulation combining clenbuterol and salbutamol for comprehensive respiratory and metabolic research applications. This advanced research compound from Ultima Pharmaceuticals enables scientists to investigate the synergistic mechanisms of two clinically relevant bronchodilator compounds in controlled laboratory environments. Researchers at Stroid UK Shop utilise this formulation to study comparative pharmacokinetics, receptor binding affinities, and downstream signalling pathways associated with beta-2 adrenergic stimulation. The compound serves as an essential tool for investigating metabolic modulation, thermogenic responses, and cardiovascular effects in various research models.
Laboratory Applications
Laboratory studies examine this dual-agonist formulation to evaluate differential receptor selectivity between clenbuterol and salbutamol compounds. Research protocols investigate the pharmacodynamic interactions when these beta-2 agonists are combined, particularly focusing on cyclic adenosine monophosphate (cAMP) elevation and downstream protein kinase A activation. Scientists studying best fat burner compounds analyse this formulation to understand metabolic pathway modulation and lipolytic enzyme activation. Additional research applications include examining bronchodilator efficacy, thermogenic potential, and cardiac beta-receptor stimulation patterns. Comparative studies utilise this compound alongside SARMs and peptides to evaluate different mechanisms of metabolic enhancement in research settings.
Compound Specifications
| Manufacturer | Ultima Pharmaceuticals |
|---|---|
| Product Code | EU13541 |
| Active Compounds | Clenbuterol + Salbutamol |
| Compound Class | Beta-2 Adrenergic Agonists |
| Formulation | Research Grade |
| Storage Requirements | Room temperature, dry conditions |
| Molecular Targets | Beta-2 adrenergic receptors |
| Research Applications | Metabolic, respiratory, cardiovascular studies |
Research Compliance
Ultima-Clen-Salbuto is manufactured exclusively for in-vitro research applications and laboratory studies. This compound is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure proper laboratory protocols, safety procedures, and regulatory compliance when handling this research chemical. All investigations should be conducted under appropriate scientific supervision with proper documentation and safety measures in place.
